NEW YORK (GenomeWeb) – Cancer genetics testing firm NeoGenomics today announced Aurora Diagnostics has selected it to be the primary partner for molecular testing in Aurora's US network of specialized pathology laboratories.
Aurora will be able to standardize oncology molecular testing services across its 19 labs as a result of the deal, NeoGenomics said.
Ft. Myers, Fla.-based NeoGenomics offers a variety of sequencing-based tests for cancers including metastatic brain cancer, metastatic breast cancer, and acute myeloid leukemia. Among its other tests, it also provides a RT-PCR- and sequencing-based test for analysis of the BCR-ABL1 fusion transcript, which can be used for the qualitative detection of mutations associated with resistance to imatinib and other tyrosine kinase inhibitors.
Financial and other terms of the deal were not disclosed.